Amneal to acquire biosimilar maker for $375 million upfront

Amneal Pharmaceuticals announced it will purchase a biosimilar development company, agreeing to pay $375 million in an upfront cash payment. The deal expands Amneal’s portfolio in the growing biosimilar market and aligns with its strategy to broaden specialty offerings.

The acquisition is expected to enhance Amneal’s manufacturing capabilities and provide access to additional pipeline candidates. Details on the target company’s name and product pipeline were not disclosed in the brief report.

Separately, workers at Samsung Bio have staged protests, though the article does not link this to the Amneal transaction. Other industry news mentioned includes updates on Avonik, a supply chain transparency bill, and Nucleus RadioPharma.